Katie Boylan
Family · Rio Rancho, NMNPI 1669885182
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,570 of the $10,716 with a category attached, or 80.0%. AbbVie accounts for 93.7% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $7,763 and has fallen 84.0% since, to $1,240 in 2025. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $142.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Lilly USA, LLC$220
- Exact Sciences$99
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$98
- Novo Nordisk$53
- AstraZeneca$43
- plus $166 from 8 others
What the payments were for
- Speaking & faculty fees$8,57080%
- Travel & lodging$9379%
- Food & beverage$1,20911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $10,038 |
| Lilly USA, LLC | 11 | $220 |
| Exact Sciences | 5 | $99 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $98 |
| Novo Nordisk | 3 | $53 |
| AstraZeneca | 3 | $43 |
| Astellas Pharma US Inc | 1 | $30 |
| Pfizer | 1 | $24 |
| Incyte Corporation | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Eko Health, Inc. | 1 | $20 |
| Medline Industries LP | 1 | $17 |
| Corcept Therapeutics | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$9,598
How this compares
$10,716 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 38 | $52,783 |
| OzempicSemaglutide | 24 | $35,626 |
| TrulicityDulaglutide | 23 | $23,361 |
| LinzessLinaclotide | 12 | $9,250 |
| EliquisApixaban | 11 | $6,601 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,355 |
| Celecoxib | 15 | $1,594 |
| Valsartan | 68 | $1,569 |
| Levothyroxine Sodium | 114 | $1,287 |
| Atorvastatin Calcium | 102 | $946 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $904 |
| Gabapentin | 86 | $877 |
| Lisinopril | 115 | $785 |
| Pregabalin | 15 | $689 |
| Tamsulosin Hcl | 49 | $670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $220 | $76,14461 claims |
| Novo NordiskOzempic | $53 | $35,62624 claims |
| AbbVieLinzess | $10,038 | $9,25012 claims |
| PfizerEliquis | $24 | $6,60111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Rio Rancho
- Anne GilbertRio Rancho$4K
- David SeiterFarmington$194K
- Carol HollandRoswell$81K
- Barbara FranklinAlbuquerque$28K
- Laurie CrockettArtesia$19K
- Kaylene CribbsFarmington$17K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Jamie LujanLas Cruces$14K
- Charles GallegosAlbuquerque$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.